Sonoma Pharmaceuticals Adjourns Special Meeting to July 22, Citing Lack of Quorum for Nevada Reincorporation Vote
SNOA sits 35% above its 52-week low of $0.85 on light trading volume (0.2× avg).
Summary
Sonoma Pharmaceuticals adjourned its Special Meeting to July 22, 2026, due to insufficient votes for its proposed reincorporation to Nevada, signaling a struggle to secure shareholder approval.
Key Events · Corporate Governance and Compliance · SNOA
-
Special Meeting Adjourned
The Special Meeting of Stockholders has been adjourned until July 22, 2026, at 2:00 p.m. local time.
-
Quorum Challenges
The adjournment is to allow stockholders additional time to vote and to establish a quorum, indicating the company has not yet received enough votes for the proposed reincorporation to Nevada.
-
Nevada Reincorporation Vote
Shareholders are being asked to vote on the reincorporation to the State of Nevada, a proposal previously noted for its potential to save $200,000 annually in taxes.
Analysis · SNOA · Industrial Applications And Services
Sonoma Pharmaceuticals has adjourned its Special Meeting of Stockholders until July 22, 2026, to allow more time for shareholders to vote on the proposed reincorporation to Nevada. The company needs to establish a quorum, indicating a challenge in securing sufficient shareholder participation for this key corporate governance change. This delay suggests potential difficulty in gaining shareholder approval for the reincorporation, which was previously highlighted as a move to save $200,000 annually in taxes.
At the time of this filing, SNOA was trading at $1.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.85 to $6.92. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.